Trial · NCT02782104
Results by group56
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 56
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Study Baseline in Computerized Cognitive Battery Domain Score: Detection Test (DET) Score | Esketamine Nasal Spray (IND Phase) | 0.0218 | Standard Deviation 0.10516 | log10 msec | |
| Change From Study Baseline in Computerized Cognitive Battery Domain Score: Detection Test (DET) Score | Esketamine Nasal Spray (OP/MA Phase) | -0.0065 | Standard Deviation 0.13526 | log10 msec | |
| Change From Study Baseline in Computerized Cognitive Battery Domain Score: Identification Test (IDN) Score | Esketamine Nasal Spray (IND Phase) | 0.0074 | Standard Deviation 0.07819 | log10 msec | |
| Change From Study Baseline in Computerized Cognitive Battery Domain Score: Identification Test (IDN) Score | Esketamine Nasal Spray (OP/MA Phase) | -0.0185 | Standard Deviation 0.09893 | log10 msec | |
| Change From Study Baseline in Computerized Cognitive Battery Domain Score: One Card Learning Test (OCL) Score | Esketamine Nasal Spray (IND Phase) | 0.0170 | Standard Deviation 0.12356 | Arcsine (sqrt of percentage of CR) | |
| Change From Study Baseline in Computerized Cognitive Battery Domain Score: One Card Learning Test (OCL) Score | Esketamine Nasal Spray (OP/MA Phase) | 0.0397 | Standard Deviation 0.15364 | Arcsine (sqrt of percentage of CR) | |
| Change From Study Baseline in Computerized Cognitive Battery Domain Score: One Back Test (ONB) Score | Esketamine Nasal Spray (IND Phase) | 0.0086 | Standard Deviation 0.08096 | log10 msec | |
| Change From Study Baseline in Computerized Cognitive Battery Domain Score: One Back Test (ONB) Score | Esketamine Nasal Spray (OP/MA Phase) | 0.0198 | Standard Deviation 0.10329 | log10 msec | |
| Change From Study Baseline in Computerized Cognitive Battery Domain Score: Groton Maze Learning Test (GMLT) Score | Esketamine Nasal Spray (IND Phase) | 1.5 | Standard Deviation 17.80 | Number of Errors | |
| Change From Study Baseline in Computerized Cognitive Battery Domain Score: Groton Maze Learning Test (GMLT) Score | Esketamine Nasal Spray (OP/MA Phase) | 5.1 | Standard Deviation 22.52 | Number of Errors | |
| Change From Study Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score | Esketamine Nasal Spray (IND Phase) | Total Recall | -0.1 | Standard Deviation 4.05 | score on a scale |
| Change From Study Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score | Esketamine Nasal Spray (OP/MA Phase) | Total Recall | 0.8 | Standard Deviation 5.05 | score on a scale |
| Change From Study Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score | Esketamine Nasal Spray (IND Phase) | Delayed Recall | 0.3 | Standard Deviation 3.81 | score on a scale |
| Change From Study Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score | Esketamine Nasal Spray (OP/MA Phase) | Delayed Recall | 0.3 | Standard Deviation 2.03 | score on a scale |
| Change From Study Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score | Esketamine Nasal Spray (IND Phase) | Total Number of True Positives | 0.1 | Standard Deviation 2.54 | score on a scale |
| Change From Study Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score | Esketamine Nasal Spray (OP/MA Phase) | Total Number of True Positives | -0.0 | Standard Deviation 2.70 | score on a scale |
| Change From Study Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score | Esketamine Nasal Spray (IND Phase) | Recognition Discrimination Index | -0.1 | Standard Deviation 2.88 | score on a scale |
| Change From Study Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score | Esketamine Nasal Spray (OP/MA Phase) | Recognition Discrimination Index | -0.1 | Standard Deviation 3.10 | score on a scale |
| Percentage of Participants Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score | Esketamine Nasal Spray (IND Phase) | Baseline: No Event | 79.8 | Percentage of participants | |
| Percentage of Participants Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score | Esketamine Nasal Spray (OP/MA Phase) | Baseline: No Event | 94.8 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02782104/results